Jaxon from United Kingdom

Registered at the short selling broker Skilling, 2 minutes ago.

» Try Skilling you too
69% of retail CFD accounts lose money.
Don't show again

Abbott Laboratories (ABT) shares information

Abbott Laboratories


24h Change

-1.37 %

ABT

Live rate: Market closed

Stock data per Tuesday 28 Mar, 2023

ABT
NEW YORK STOCK EXCHANGE INC.
98.46
98.1
97.11
-1.35 (-1.37%)
US Market is closed

Live Stock price in graph for Abbott Laboratories (ABT)

  • Latest Volume

    4,815,443 (4.05 %)

  • Volume prev. day

    4,627,788

  • Avg. daily volume

    5,637,867

  • Market cap

    168,771,958,687

  • P/E ratio

    24.71

  • Today high

    98.24 USD

  • Today low

    96.61 USD

  • 52 week high

    122.66 USD

  • 52 week low

    92.83 USD

  • YTD Change

    n/a

Quick links

 

Latest news about Abbott Laboratories

Below you can find the most recent news posts about Abbott Laboratories, primarily from US and UK based news sources.

UBS new coverage Abbott Labs Buy

Tuesday, 28 March 2023, 22:42:34
https://www.investing.com/news/pro/abbott-laboratories-receives-investment-bank-analyst-rating-update-3043086
— Investing.com


Pulmonary Valve Replacement Market to Reach USD 1.6 Bn by 2031 | Transparency Market Research

Tuesday, 28 March 2023, 18:33:00
WILMINGTON, DE / ACCESSWIRE / March 28, 2023 / Transparency Market Research Inc. – The pulmonary valve replacement market was valued at USD 1.0 Bn in 2022 and is projected to surpass USD 1.6 Bn by 2031 with CAGR of 4.9%. Rise in number of transcatheter heart valve replacement procedures in developed countries in the past few years has helped augment the pulmonary valve replacement market size. Advancements in diagnosis of pulmonary valve disorders are likely to bolster the market development. Request for a Sample PDF Report with Latest Industry Insights: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=85497 Surge in prevalence of congenital heart diseases (CHD) in adults in several countries is likely to bolster the demand for pulmonary valve replacement procedures. Rapid increase in number of adults with CHD is driving the need for revised guidelines on the management of adult CHD. These guidelines should focus on risk assessment and the type of interventions that would prove effective in the treatment of the disease.
— Accesswire


Republicans Seek Documents, Schedule Hearing Related To FDA”s Response To Baby-Formula Shortage

Tuesday, 21 March 2023, 20:37:56
House Republicans are reportedly speeding up their scrutiny of the FDA and the White House”s handling of the baby formula shortage last year. The supply crunch hit the U.S. market when Abbott Laboratories (NYSE: ABT ), a significant supplier, closed its Sturgis, Michigan, plant due to bacterial infection. House Oversight and Accountability Committee Chairman James Comer (R., Ky.) and Rep. Lisa McClain (R., Mich.), who leads its panel on healthcare, asked the FDA to submit all communications between the agency, White House staff, and the Health and Human Services Department … Full story available on Benzinga.com
— Benzinga


Abbott Labs: Steadily Getting Back To Normal

Monday, 20 March 2023, 16:10:25
Abbott has had a crazy couple of years, with a formula recall and a COVID testing boom. Find out why I rate ABT stock a hold.
— Seeking Alpha


Abbott Laboratories Stock: A Dividend King At A Discount (NYSE:ABT)

Monday, 20 March 2023, 09:46:37
Abbott comes with a decent dividend yield and sustainable dividend growth backed by a wide-moat business model. Read why ABT stock is a Buy.
— Seeking Alpha


Trading broker recommendation

We recommend that you check out Capital.com as they have a very good selection of stocks available for both going short and long.

Rating: 9.57/10
Minimum deposit: €250 by bank
Description: Capital.com offer a large number of stocks for trading. Register an account today and check if they have ABT available or trade one of the many other CFD stocks they have.
Risk warning: 67.7% of retail investor accounts lose money when trading CFDs with Capital.